Microsatellite instability and survival outcomes in endometrial cancer: a comprehensive analysis of molecular subtypes and clinical implications

Background: Microsatellite instability (MSI) is a key biomarker in endometrial cancer, present in 20–30% of cases. The prognostic significance of MSI status, particularly MSI-high (MSI-H), remains under investigation, with conflicting reports on survival outcomes. This study aimed to evaluate the impact of MSI on overall and disease-free survival in endometrial carcinoma patients and compare characteristics between MSI-H and microsatellite stable (MSS) tumors. Methods: We retrospectively analyzed 100 patients with surgically treated endometrial carcinoma from March 2018 to March 2024. Patients were grouped as MSI-H or MSS based on immunohistochemical analysis of mismatch repair (MMR) proteins (MLH1 (mutL homolog 1), MSH2 (mutS homolog 2), MSH6 (mutS homolog 6), and PMS2 (postmeiotic segregation increased 2)) in formalin-fixed, paraffin-embedded (FFPE) tissue. We collected and analyzed clinicopathological data, including demographics, tumor features, molecular data, treatments, and survival outcomes. Results: Of the 100 patients, 34 (34%) were MSI-H and 66 (66%) were MSS. No significant differences were found in age, body mass index, or preoperative Cancer Antigen 125 (CA-125) levels. MSI-H tumors were significantly larger (median 65 mm vs. 45 mm, p < 0.001), had higher rates of mucinous differentiation (52.9% vs. 24.2%, p = 0.008), and more frequent poor differentiation (20.6% vs. 3.03%, p = 0.003). MSI-H status was also associated with more advanced-stage disease. The most common MMR protein losses were in PMS2 (79.2%) and MLH1 (67.6%). Over a median follow-up of 48 months, the 5-year overall and disease-free survival rates for the entire cohort were 71.3% and 67.9%, respectively. Conclusions: Although MSI-H endometrial carcinomas have distinct pathological features, MSI status did not significantly affect survival in this cohort. These findings suggest that MSI testing is more valuable as a predictive biomarker for immunotherapy than for prognostic purposes. Comprehensive molecular profiling, including p53 and DNA polymerase epsilon (POLE) analysis, is necessary for a complete understanding of prognosis in endometrial carcinoma.

Microsatellite instability; Endometrial carcinoma; Mismatch repair deficiency; Molecular classification; Survival analysis; Immunotherapy

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. International Journal of Cancer. 2021; 149: 778–789.

[3] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[4] Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations and recent progress in endometrial cancer. CA: A Cancer Journal for Clinicians. 2019; 69: 258–279.

[5] Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[6] Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. British Journal of Cancer. 2015; 113: 299–310.

[7] Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138: 2073–2087.

[8] Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine. 2005; 352: 1851–1860.

[9] Peltomäki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. Journal of Clinical Oncology. 2003; 21: 1174–1179.

[10] Galant N, Krawczyk P, Monist M, Obara A, Gajek Ł, Grenda A, et al. Molecular classification of endometrial cancer and its impact on therapy selection. International Journal of Molecular Sciences. 2024; 25: 5893.

[11] Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nature Reviews Clinical Oncology. 2010; 7: 153–162.

[12] Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. Journal of Clinical Oncology. 2007; 25: 2042–2048.

[13] Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895–2015. Nature Reviews Cancer. 2015; 15: 181–194.

[14] Kunkel TA, Erie DA. DNA mismatch repair. Annual Review of Biochemistry. 2005; 74: 681–710.

[15] Modrich P. Mechanisms in eukaryotic mismatch repair. Journal of Biological Chemistry. 2006; 281: 30305–30309.

[16] Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 1998; 17: 2413–2417.

[17] Garg K, Soslow RA. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. Journal of Clinical Pathology. 2009; 62: 679–684.

[18] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine. 2015; 372: 2509–2520.

[19] Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clinical Cancer Research. 2019; 25: 3753–3758.

[20] Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology. 2020; 38: 1–10.

[21] Slomovitz BM, Cibula D, Lv W, Ortaç F, Hietanen S, Backes F, et al. Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: results in mismatch repair-deficient tumors. Journal of Clinical Oncology. 2024; 43: 251–259.

[22] Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. The New England Journal of Medicine. 2023; 388: 2145–2158.

[23] Powell MA, Bjørge L, Willmott L, Novák Z, Black D, Gilbert L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Annals of Oncology. 2024; 35: 728–738.

[24] Wada M, Yamagami W. Immunotherapy for endometrial cancer. International Journal of Clinical Oncology. 2025; 30: 449–456.

[25] Ogunmuyiwa J, Williams V. Emerging advances in endometrial cancer: integration of molecular classification into staging for enhanced prognostic accuracy and implications for racial disparities. Cancers. 2024; 16: 1172.

[26] León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. The Journal of Pathology. 2020; 250: 323–335.

[27] Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern Pathology. 2015; 28: 836–844.

[28] Pizzimenti C, Fiorentino V, Pepe L, Franchina M, Ruggeri C, Ercoli A, et al. Predictive biomarkers for immunotherapy in endometrial carcinoma. Cancers. 2025; 17: 2420.

[29] Dong Y, Zhao L, Kang N, Wang Y, Li H, Wang Z, et al. Chinese expert consensus on clinical application of molecular classification of endometrial cancer (2024). Gynecology and Obstetrics Clinical Medicine. 2025; 5: e000148.

[30] Andrade DAP, Bonatelli M, de Paula FE, Berardinelli GN, Teixeira GR, Dos Reis MT, et al. Implementation of the ProMisE classifier and validation of its prognostic impact in Brazilian endometrial carcinomas. Frontiers in Oncology. 2024; 14: 1503901.

[31] Pacholczak-Madej R, Bartoletti M, Musacchio L, Püsküllüoglu M, Blecharz P, Lorusso D. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer. Expert Review of Anticancer Therapy. 2024; 24: 717–729.

[32] Tang Y, Chen Y, Zeng T, Huang K, Zhao J, Zhang P, et al. Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis. Future Science OA. 2025; 11: 2541517.

[33] Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. International Journal of Gynecology & Obstetrics. 2023; 162: 383–394.

[34] Zheng W. Molecular classification of endometrial cancer and the 2023 FIGO staging: exploring the challenges and opportunities for pathologists. Cancers. 2023; 15: 4101.

[35] Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107: 6982–6987.

[36] Manning-Geist BL, Liu YL, Devereaux KA, Paula ADC, Zhou QC, Ma W, et al. Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles. Clinical Cancer Research. 2022; 28: 4302–4311.

[37] Dal Buono A, Puccini A, Franchellucci G, Airoldi M, Bartolini M, Bianchi P, et al. Lynch syndrome: from multidisciplinary management to precision prevention. Cancers. 2024; 16: 849.

[38] Kurpiel B, Thomas MS, Mubeen M, Ring KL, Modesitt SC, Moskaluk CA, et al. MLH1/PMS2-deficient endometrial carcinomas in a universally screened population: MLH1 hypermethylation and germline mutation status. International Journal of Gynecological Pathology. 2022; 41: 1–12.

[39] Tang M, Yin S, Zeng H, Huang A, Huang Y, Hu Z, et al. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. Cell Death and Disease. 2024; 15: 69.

[40] Eikenboom EL, van Leeuwen L, Groenendijk F, Woolderink JM, Van Altena AM, Van Leerdam ME, et al.; Collaborative Investigators from the Dutch Foundation for Detection of Hereditary Tumors. Outcomes of endometrial cancer prevention strategies in patients with Lynch syndrome: a nationwide cohort study in the Netherlands. eClinicalMedicine. 2025; 79: 103006.

[41] Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006; 106: 87–94.

[42] Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. Journal of Clinical Oncology. 2005; 23: 609–618.

[43] McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Journal of Clinical Oncology. 2016; 34: 3062–3068.

[44] Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. The New England Journal of Medicine. 2003; 349: 247–257.

[45] Bruno V, Betti M, D’Ambrosio L, Massacci A, Chiofalo B, Pietropolli A, et al. Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework. International Journal of Gynecological Cancer. 2023; 33: 1708–1714.

[46] Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, placebo-controlled phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Annals of Oncology. 2024; 35: 968–980.

[47] Bujnak AC, File B, Tewari KS. Clinical use of dostarlimab in advanced stage and recurrent endometrial cancer: patient selection and perspectives. Cancer Management and Research. 2025; 17: 161–170.

[48] Antill Y, Kok PS, Robledo K, Barnes E, Friedlander M, Baron-Hay SE, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). Journal of Clinical Oncology. 2021; 39: 5581.

[49] León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al.; TransPORTEC consortium. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. Journal of Clinical Oncology. 2020; 38: 3388–3397.

[50] GSK Press Release. European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer. 2025. Available at: https://www.gsk.com/en-gb/media/press-releases/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ (Accessed: 20 January 2025).

[51] Huang D, Li S, Bai Y, Wang Y. Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis. BMC Cancer. 2024; 24: 1298.

[52] Mendiola M, Heredia-Soto V, Ruz-Caracuel I, Baillo A, Ramon-Patino JL, Berjon A, et al. Performance of the Idylla microsatellite instability test in endometrial cancer. Molecular and Cellular Probes. 2024; 77: 101976.

[53] Anca-Stanciu MB, Manu A, Olinca MV, Coroleucă C, Comandașu DE, Coroleuca CA, et al. Comprehensive review of endometrial cancer: new molecular and FIGO classification and recent treatment changes. Journal of Clinical Medicine. 2025; 14: 1385.

[54] Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123: 802–813.

[55] Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Annals of Oncology. 2018; 29: 1180–1188.

[56] Nero C, Trozzi R, Persiani F, Rossi S, Mastrantoni L, Duranti S, et al. POLE mutations in endometrial carcinoma: clinical and genomic landscape from a large prospective single-center cohort. Cancer. 2025; 131: e35731.

[57] Edwards P, Monahan KJ. Diagnosis and management of Lynch syndrome. Frontline Gastroenterol. 2022; 13: e80–e87.

[58] Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116: 1453–1456.

[59] Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. American Journal of Gastroenterology. 2014; 109: 1159–1179.

[60] Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. Journal of Clinical Oncology. 2012; 30: 958–964.

[61] Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England Journal of Medicine. 2006; 354: 261–269.

[62] Fanale D, Corsini LR, Piraino P, Pedone E, Brando C, Bazan Russo TD, et al. POLE-mutated endometrial cancer: new perspectives on the horizon? Frontiers in Oncology. 2025; 15: 1633260.

[63] Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2020; 76: 52–63.

[64] Di Dio C, Bogani G, Di Donato V, Cuccu I, Muzii L, Musacchio L, et al. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Gynecologic Oncology. 2023; 169: 27–33.

[65] Cosgrove CM, Zamarin D, Conejo-Garcia JR, Hacker KE, Vargas R, Konstantinopoulos PA, et al. A working group report from the 2024 National Cancer Institute/Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era. Journal of the National Cancer Institute. 2025; 117: 1774–1783.

[66] Moore KN, Liu JF, Lorusso D. State of the art: therapies now and around the corner for gynecologic cancers. American Society of Clinical Oncology Educational Book. 2025; 45: e473114.

[67] Koskas M, Crosbie EJ, Fokdal L, McCluggage WG, Mileshkin L, Mutch DG, et al. Cancer of the corpus uteri: a 2025 update. International Journal of Gynaecology and Obstetrics. 2025; 171: 60–77.

[68] Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022; 33: 860–877.

[69] Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. The Lancet Oncology. 2025; 26: e423–e435.

[70] Ren J, Wang J, Wang Y, Yang D, Sheng J, Zhu S, et al. Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials. Frontiers in Immunology. 2025; 16: 1521362.

[71] O’Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, Acosta ADJ, et al. Pembrolizumab in microsatellite instability-high/mismatch repair-deficient advanced endometrial cancer. Gynecologic Oncology. 2025; 193: 130–135.

[72] Kokori E, Olatunji G, Abdulbasit M, Aderinto N. The efficacy and safety of pembrolizumab and dostarlimab in endometrial cancer. Springer. 2024; 1: 46.

[73] Zhao X, She L, Liu X, Bi Z. Pembrolizumab plus chemotherapy in advanced endometrial cancer. Cost Effectiveness and Resource Allocation. 2025; 23: 29.

[74] Pan B, Lai X, Lu J, Bao X, Fan Z, Sun J. Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis. Frontiers in Oncology. 2025; 14: 1511301.